An announcement from Allergy Therapeutics ( (GB:AGY) ) is now available.
Allergy Therapeutics announced its participation in the 2025 AAAAI/WAO Joint Congress, where it will present scientific advancements in its pollen and food-allergy research portfolio. The company will showcase six posters, including a positive comparative assessment of its Grass MATA MPL immunotherapy, design details of a Phase III trial for grass allergies in children, and safety data from a clinical trial of a peanut allergy vaccine. These developments highlight Allergy Therapeutics’ commitment to innovation and its efforts to transform patient lives through advanced therapies.
More about Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company based in the UK, specializing in the treatment and diagnosis of allergic disorders. The company focuses on developing aluminium-free immunotherapies that have the potential to cure diseases. It operates in nine major European countries and has distribution agreements in an additional ten countries.
YTD Price Performance: 7.69%
Average Trading Volume: 479,817
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £333.7M
See more data about AGY stock on TipRanks’ Stock Analysis page.